Cargando…

CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease

BACKGROUND: Increasing evidence suggests that microglial activation may participate in the aetiology and pathogenesis of Parkinson's disease (PD). CD200-CD200R signalling has been shown to be critical for restraining microglial activation. We have previously shown that expression of CD200R in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shi, Wang, Xi-Jin, Tian, Li-Peng, Pan, Jing, Lu, Guo-Qiang, Zhang, Ying-Jie, Ding, Jian-Qing, Chen, Sheng-Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226566/
https://www.ncbi.nlm.nih.gov/pubmed/22053982
http://dx.doi.org/10.1186/1742-2094-8-154
_version_ 1782217642416799744
author Zhang, Shi
Wang, Xi-Jin
Tian, Li-Peng
Pan, Jing
Lu, Guo-Qiang
Zhang, Ying-Jie
Ding, Jian-Qing
Chen, Sheng-Di
author_facet Zhang, Shi
Wang, Xi-Jin
Tian, Li-Peng
Pan, Jing
Lu, Guo-Qiang
Zhang, Ying-Jie
Ding, Jian-Qing
Chen, Sheng-Di
author_sort Zhang, Shi
collection PubMed
description BACKGROUND: Increasing evidence suggests that microglial activation may participate in the aetiology and pathogenesis of Parkinson's disease (PD). CD200-CD200R signalling has been shown to be critical for restraining microglial activation. We have previously shown that expression of CD200R in monocyte-derived macrophages, induced by various stimuli, is impaired in PD patients, implying an intrinsic abnormality of CD200-CD200R signalling in PD brain. Thus, further in vivo evidence is needed to elucidate the role of malfunction of CD200-CD200R signalling in the pathogenesis of PD. METHODS: 6-hydroxydopamine (6-OHDA)-lesioned rats were used as an animal model of PD. CD200R-blocking antibody (BAb) was injected into striatum to block the engagement of CD200 and CD200R. The animals were divided into three groups, which were treated with 6-OHDA/Veh (PBS), 6-OHDA/CAb (isotype control antibody) or 6-OHDA/BAb, respectively. Rotational tests and immunohistochemistry were employed to evaluate motor deficits and dopaminergic neurodegeneration in animals from each group. HPLC analysis was used to measure monoamine levels in striatum. Morphological analysis and quantification of CD11b- (or MHC II-) immunoreactive cells were performed to investigate microglial activation and possible neuroinflammation in the substantia nigra (SN). Finally, ELISA was employed to assay protein levels of proinflammatory cytokines. RESULTS: Compared with 6-OHDA/CAb or 6-OHDA/Veh groups, rats treated with 6-OHDA/BAb showed a significant increase in counts of contralateral rotation and a significant decrease in TH-immunoreactive (TH-ir) neurons in SN. A marked decrease in monoamine levels was also detected in 6-OHDA/BAb-treated rats, in comparison to 6-OHDA/Veh-treated ones. Furthermore, remarkably increased activation of microglia as well as up-regulation of proinflammatory cytokines was found concomitant with dopaminergic neurodegeneration in 6-OHDA/BAb-treated rats. CONCLUSIONS: This study shows that deficits in the CD200-CD200R system exacerbate microglial activation and dopaminergic neurodegeneration in a 6-OHDA-induced rat model of PD. Our results suggest that dysfunction of CD200-CD200R signalling may be involved in the aetiopathogenesis of PD.
format Online
Article
Text
id pubmed-3226566
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32265662011-11-30 CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease Zhang, Shi Wang, Xi-Jin Tian, Li-Peng Pan, Jing Lu, Guo-Qiang Zhang, Ying-Jie Ding, Jian-Qing Chen, Sheng-Di J Neuroinflammation Research BACKGROUND: Increasing evidence suggests that microglial activation may participate in the aetiology and pathogenesis of Parkinson's disease (PD). CD200-CD200R signalling has been shown to be critical for restraining microglial activation. We have previously shown that expression of CD200R in monocyte-derived macrophages, induced by various stimuli, is impaired in PD patients, implying an intrinsic abnormality of CD200-CD200R signalling in PD brain. Thus, further in vivo evidence is needed to elucidate the role of malfunction of CD200-CD200R signalling in the pathogenesis of PD. METHODS: 6-hydroxydopamine (6-OHDA)-lesioned rats were used as an animal model of PD. CD200R-blocking antibody (BAb) was injected into striatum to block the engagement of CD200 and CD200R. The animals were divided into three groups, which were treated with 6-OHDA/Veh (PBS), 6-OHDA/CAb (isotype control antibody) or 6-OHDA/BAb, respectively. Rotational tests and immunohistochemistry were employed to evaluate motor deficits and dopaminergic neurodegeneration in animals from each group. HPLC analysis was used to measure monoamine levels in striatum. Morphological analysis and quantification of CD11b- (or MHC II-) immunoreactive cells were performed to investigate microglial activation and possible neuroinflammation in the substantia nigra (SN). Finally, ELISA was employed to assay protein levels of proinflammatory cytokines. RESULTS: Compared with 6-OHDA/CAb or 6-OHDA/Veh groups, rats treated with 6-OHDA/BAb showed a significant increase in counts of contralateral rotation and a significant decrease in TH-immunoreactive (TH-ir) neurons in SN. A marked decrease in monoamine levels was also detected in 6-OHDA/BAb-treated rats, in comparison to 6-OHDA/Veh-treated ones. Furthermore, remarkably increased activation of microglia as well as up-regulation of proinflammatory cytokines was found concomitant with dopaminergic neurodegeneration in 6-OHDA/BAb-treated rats. CONCLUSIONS: This study shows that deficits in the CD200-CD200R system exacerbate microglial activation and dopaminergic neurodegeneration in a 6-OHDA-induced rat model of PD. Our results suggest that dysfunction of CD200-CD200R signalling may be involved in the aetiopathogenesis of PD. BioMed Central 2011-11-06 /pmc/articles/PMC3226566/ /pubmed/22053982 http://dx.doi.org/10.1186/1742-2094-8-154 Text en Copyright ©2011 Zhang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Zhang, Shi
Wang, Xi-Jin
Tian, Li-Peng
Pan, Jing
Lu, Guo-Qiang
Zhang, Ying-Jie
Ding, Jian-Qing
Chen, Sheng-Di
CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease
title CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease
title_full CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease
title_fullStr CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease
title_full_unstemmed CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease
title_short CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease
title_sort cd200-cd200r dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of parkinson's disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226566/
https://www.ncbi.nlm.nih.gov/pubmed/22053982
http://dx.doi.org/10.1186/1742-2094-8-154
work_keys_str_mv AT zhangshi cd200cd200rdysfunctionexacerbatesmicroglialactivationanddopaminergicneurodegenerationinaratmodelofparkinsonsdisease
AT wangxijin cd200cd200rdysfunctionexacerbatesmicroglialactivationanddopaminergicneurodegenerationinaratmodelofparkinsonsdisease
AT tianlipeng cd200cd200rdysfunctionexacerbatesmicroglialactivationanddopaminergicneurodegenerationinaratmodelofparkinsonsdisease
AT panjing cd200cd200rdysfunctionexacerbatesmicroglialactivationanddopaminergicneurodegenerationinaratmodelofparkinsonsdisease
AT luguoqiang cd200cd200rdysfunctionexacerbatesmicroglialactivationanddopaminergicneurodegenerationinaratmodelofparkinsonsdisease
AT zhangyingjie cd200cd200rdysfunctionexacerbatesmicroglialactivationanddopaminergicneurodegenerationinaratmodelofparkinsonsdisease
AT dingjianqing cd200cd200rdysfunctionexacerbatesmicroglialactivationanddopaminergicneurodegenerationinaratmodelofparkinsonsdisease
AT chenshengdi cd200cd200rdysfunctionexacerbatesmicroglialactivationanddopaminergicneurodegenerationinaratmodelofparkinsonsdisease